Olesya Shershen is Global IT Finance solutions lead a UCB Biopharma.

Having more then 10 years experience in Finance IT transformation, Olesya worked with different technologies and products, such as RPA (tasks bots, cognitive bots), Chatbots, Analytics (Reporting dashboards), Business Development platform (INOVA); SAP ERP(S4 as well) and MS Dynamics CRM.

She is passionate in steering complex transformations and considers herself as digital evolution driver.

2018: the automation business case published in Financial Director magazine (awarded as best Finance Team in 2018); successful continuous improvement of the digital roadmap is communicated at several conferences: Cognitive Business Automation and Cognitive Finance (2018, 2019), ScaleUp360 (2019, early 2020).

UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With more than 7500 employees in approximately 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules and no major patent expiration in the next decade; - About 25% of 2016 revenue reinvested into Research & Development - 2016 Key Financials: €4.2 billion global revenue